3030 related articles for article (PubMed ID: 17631760)
21. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
Sangoi AR; McKenney JK; Dadras SS; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
[TBL] [Abstract][Full Text] [Related]
22. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
23. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
25. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
Zhang MZ; Qiao YH; Suo ZH
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
[TBL] [Abstract][Full Text] [Related]
26. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
28. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721
[TBL] [Abstract][Full Text] [Related]
29. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
31. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
32. Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.
Motohara T; Tashiro H; Miyahara Y; Sakaguchi I; Ohtake H; Katabuchi H
Cancer Sci; 2010 Jun; 101(6):1550-6. PubMed ID: 20384630
[TBL] [Abstract][Full Text] [Related]
33. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
[TBL] [Abstract][Full Text] [Related]
34. Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
Köbel M; Kalloger SE; Huntsman DG; Santos JL; Swenerton KD; Seidman JD; Gilks CB;
Int J Gynecol Pathol; 2010 May; 29(3):203-11. PubMed ID: 20407318
[TBL] [Abstract][Full Text] [Related]
35. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
[TBL] [Abstract][Full Text] [Related]
37. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
38. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.
Buchynska LG; Nesina IP; Yurchenko NP; Bilyk OO; Grinkevych VN; Svintitsky VS
Exp Oncol; 2007 Mar; 29(1):49-53. PubMed ID: 17431389
[TBL] [Abstract][Full Text] [Related]
39. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
40. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
